Introducing the new CRA Life Sciences series: Innovation in neuroscience.
Advances in neuroscience are reshaping our understanding of the brain and opening new frontiers in how we diagnose, treat, and ultimately prevent neurological disease. The next decade could be defined by breakthroughs in neuroscience that translate scientific discovery into meaningful patient impact. To explore this rapidly evolving landscape, CRA Life Sciences is launching a multi-part series that will explore “Innovation in Neuroscience,” and examine the scientific, technological, and strategic forces driving progress across the field.
The first part of the series, “A new era in CNS drug delivery: Crossing the blood-brain barrier,” authored by Tunahan Kirabali, dives into one of the most critical challenges in neuroscience today: enabling safe, effective, and targeted delivery of therapeutics to the central nervous system. As emerging modalities, from gene therapies to biologics, push the boundaries of what is possible, overcoming the blood-brain barrier has become essential to unlocking the full potential of next‑generation treatments.
This introductory article delves into the reasons behind the growing strategic significance of the topic and examines the increasing focus it is receiving across the industry.
